Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
- Conditions
- Advanced NSCLCAdvanced Endometrial Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 282
- Registration Number
- NCT06758557
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
A Phase 2 Study to Explore the Efficacy and Safety of HB0017 Longer Dose Interval in Psoriasis Patients
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06592274
- Locations
- 🇨🇳
Shandong First Medical University Affiliated Dermatology Hospital, Jinan, Shandong, China
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06477237
- Locations
- 🇨🇳
Jiangmen Central Hospital, Jiangmen, Guangdong, China
🇨🇳Nanyang First People's Hospital, Nanyang, Henan, China
🇨🇳Beijing Friendship Hospital, Beijing, China
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06222125
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of HB0030 Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05706207
- Locations
- 🇨🇳
the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- Prev
- 1
- 2
- 3
- Next